Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection
Prescription Required
Product introduction
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains two monoclonal antibodies used together for the emergency treatment of mild to moderate COVID-19 in adults and children aged 12 years and above and over 40 kg in weight. It is most effective if taken after an early laboratory diagnosis (within 7 to 10 days).
This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021. Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries.
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup. This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis). Patients should be monitored during and at least 1 hour after the injection.
The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, let your doctor know immediately.
Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions. Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug. This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.
Contact Us
If you want to know about the medicine availability or need help to identify where you can get it administered, please fill in your details here and we will reach out to you.
This monoclonal antibody cocktail received emergency use approval from the Central Drug Standard Control Organization (CDSCO) on May 3rd, 2021. Apart from India, it has been approved for use in the United States, Switzerland, Germany, Italy, France, and several other countries.
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection should be given either into a vein (intravenously) or below the skin (subcutaneously) by a trained healthcare professional, preferably in a hospital setup. This is because the use of monoclonal antibodies may cause some side effects that may need immediate medical attention, such as severe allergic reactions (anaphylaxis). Patients should be monitored during and at least 1 hour after the injection.
The most common side effects of this monoclonal antibody therapy are injection site reactions, fever, flushing, shortness of breath, chest tightness, nausea, and vomiting. If you experience any of these side effects, let your doctor know immediately.
Before receiving this medicine, let your doctor know if you have any pre-existing medical conditions. Let the doctor know about your other medications if any, as they may affect or get affected by this COVID-19 drug. This medicine may be given to pregnant or breastfeeding women after considering its benefits against the risk to the baby or the mother.
Contact Us
If you want to know about the medicine availability or need help to identify where you can get it administered, please fill in your details here and we will reach out to you.
Uses of Casirivimab & Imdevimab Injection
- Treatment of Mild to moderate Coronavirus disease (COVID-19)
Benefits of Casirivimab & Imdevimab Injection
In Treatment of Mild to moderate Coronavirus disease (COVID-19)
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection contains monoclonal antibodies that help manage mild to moderate COVID-19 symptoms in those individuals who are at a high risk of developing severe COVID-19 infection and do not need oxygen administration. This medicine may help you to recover from the infection if diagnosed early before hospitalization. If you think you have come in contact with an infected person, or feel any of the symptoms, consult your doctor immediately.
Side effects of Casirivimab & Imdevimab Injection
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Casirivimab & Imdevimab
- Injection site reactions (pain, swelling, redness)
- Fever
- Flushing (sense of warmth in the face, ears, neck and trunk)
- Breathlessness
- Chest tightness
- Nausea
- Vomiting
How to use Casirivimab & Imdevimab Injection
Your doctor or nurse will give you this medicine. Kindly do not self administer.
How Casirivimab & Imdevimab Injection works
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is a combination of two human immunoglobulins G-1 (IgG1), neutralizing monoclonal antibodies, that bind at different sites on the spike protein of SARS-CoV-2, the virus that causes COVID-19. This unique binding mechanism, developed using recombinant DNA technology, is equally effective against the existing as well as newer emerging variants and prevents the virus from attaching to the human cell receptors.
Safety advice
Alcohol
CONSULT YOUR DOCTOR
It is not known whether it is safe to consume alcohol with Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection. Please consult your doctor.
Pregnancy
CONSULT YOUR DOCTOR
Information regarding the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection during pregnancy is not available. Please consult your doctor.
Breast feeding
CONSULT YOUR DOCTOR
Information regarding the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection during breastfeeding is not available. Please consult your doctor.
Driving
SAFE
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection does not usually affect your ability to drive.
Kidney
SAFE IF PRESCRIBED
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is probably safe to use in patients with kidney disease. Limited data available suggests that dose adjustment of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection may not be needed in these patients. Please consult your doctor.
Liver
CONSULT YOUR DOCTOR
There is limited information available on the use of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection in patients with liver disease. Please consult your doctor.
What if you forget to take Casirivimab & Imdevimab Injection?
If you miss a dose of Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
No substitutes found for this medicine
Quick tips
- Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, a monoclonal antibody cocktail therapy, is used to treat mild to moderate symptoms of COVID-19 in non-hospitalized adults and adolescents aged 12 years and older, who weigh at least 40 kg.
- The use of monoclonal antibodies is not indicated in severe hospitalized cases of COVID-19 or in those who require oxygen therapy.
- Even after the treatment, you should continue to practice (COVID)-appropriate behavior such as wearing a mask, social distancing, avoiding sharing personal items, and frequent handwashing.
- Before taking this antibody cocktail therapy, inform your doctor if you have any underlying medical conditions like diabetes, heart disease, high blood pressure, kidney disease, asthma, etc.
- Patients should be monitored during treatment and at least one hour after the completion of the infusion.
- Severe allergic reactions might happen during and after the use of monoclonal antibodies. Inform your doctor or nurse immediately if you experience shortness of breath, rapid or slow heart rate, chest pain, swelling of the face or lips, sweating.
Fact Box
Habit Forming
No
Patient concerns
FAQs
What are monoclonal antibodies? How are they relevant to Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection?
Monoclonal antibodies are specific proteins that mimic the immune system’s ability to fight against harmful microorganisms like viruses. Casirivimab and Imdevimab, the monoclonal antibodies present in Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection, help protect against the deadly SARS-CoV-2, the virus that causes COVID-19.
What is a monoclonal antibody cocktail?
A monoclonal antibody cocktail is a combination of monoclonal antibodies that are available separately, but are mixed together for use as a cocktail, hence the name.
How are monoclonal antibodies helpful in treating COVID-19?
SARS-CoV-2, the virus that causes COVID-19, has a spike protein on its surface that helps the virus to attach and enter the hu n body. Monoclonal antibodies are engineered to mimic this attachment with SARS-CoV-2, thereby preventing disease progression. Monoclonal antibody therapy may help in treating mild symptoms at the initial stages.
When should monoclonal antibody therapy for COVID-19 be taken?
Monoclonal antibody therapy for COVID-19 should be taken after the early diagnosis of COVID-19 in patients aged 12 years or older with a bodyweight of at least 40 kg. It may also be taken by people who are at a high risk of developing a severe infection, such as those aged 60 years or above, who have comorbidities such as diabetes or hypertension, and those who are immunocompromised.
Who should not take monoclonal antibodies for COVID-19?
Monoclonal antibodies for COVID-19 should not be taken by those who are hospitalized or need oxygen therapy. Additionally, it should not be taken by those under oxygen treatment due to pre-existing comorbidities that may not be associated with COVID-19. Those who are allergic to any of the two medicines in Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection or any of the other ingredients of the kit should also avoid taking this combination of monoclonal antibodies.
Who is at high risk of developing severe COVID-19?
People aged above 60 years, who are obese, have comorbid conditions related to lungs, kidneys (like dialysis patients), liver, or those who have a weak immunity (like cancer patients) are at high risk of developing severe COVID-19.
How is Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection used?
Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection is given as an injection into a vein (intravenously) or below the skin (subcutaneously), by a healthcare professional, in a hospital to treat mild to moderate symptoms of COVID-19. It should never be injected into a muscle (intramuscularly).
I have high blood pressure and diabetes. Can I take Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection?
Yes, Casirivimab & Imdevimab Combo Pack 120mg/120mg Injection can be taken by patients with high blood pressure or diabetes, if prescribed. As per the available data, the benefits of using monoclonal antibody therapy are more significant than the potential risks.
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Clinica Trials Arena. REGEN-COV (Casirivimab with Imdevimab) for the Treatment of Mild to Moderate Covid-19. [Accessed 07 Jul. 2021] (online) Available from:
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. N Engl J Med. 2021;384(3):238-51. [Accessed 07 Jul. 2021] (online) Available from:
- Casirivimab 120mg/ml and Imdevimab 120mg/ml Injection [Product Information]. Mumbai, Maharashtra: Cipla Ltd.; 2021. [Accessed 6th Jan. 2022] (online) Available from:
- Cipla. Ronapreve (Casirivimab and Imdevimab) [Product Monograph]. [Accessed 6th Jan. 2022] (online) Available from:
- Lloyd EC, Gandhi TN, Petty LA. Monoclonal Antibodies for COVID-19. JAMA. 2021;325(10):1015. [Accessed 6th Jan. 2022] (online) Available from:
- Cipla. Mumbai, 24th May 2021. Press Release: Roche & Cipla announce the arrival of the first batch of the new antibody cocktail drug (Casivirimab and Imdevimab) in India. [Accessed 06 Jan. 2022] (online) Available from:
Marketer details
Name: Cipla Ltd
Address: Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400013
Country of origin: India
Lab tests offered by us
Related/Popular tests
MRP
₹119500
Inclusive of all taxes
1.0 Injection in 1 vial
SOLD OUT
Notify me